undamentalytics Newsletter
Sign in

Quidelortho Corp (QDEL) stock

Add to watchlist

Add holding +

NASDAQ: QDEL Nasdaq Health Care Equipment Next results ~November 3, 2026

C Fundamentals grade

Quidelortho Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$39

Price-to-sales vs peers

Base case. Range ~$39–$190. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Quidelortho Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders6 buying, 1 selling9 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds138 adding, 113 cuttingOf 38 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Quidelortho files

Where Quidelortho stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.67bn, down 2.5% on a year earlier, a smaller fall than the 3.9% decline a quarter earlier. That puts it 25 of 25 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to -7.9% from 0.5% a year earlier. Operating margin narrowed to -30.8% from -8.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $1.12 a share, against a share price of $13.47.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Quidelortho Corp's trailing-twelve-month revenue fell 2.5% year on year, with a free-cash-flow margin of -7.9%. Where it lags: long-term debt as % of assets of 44.4% ranks 71 of 87 health care equipment companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 375% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Quidelortho Corp's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 2.5% over the last 12 months.
  • Loss-making. Operating margin is -30.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 22.3 points on a year ago.
  • Burning cash. Free cash flow was -7.9% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 91% and a beta of 2.6 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 44.4% ranks 71 of 87 health care equipment companies we cover (median 24.2%).

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
$0.13 against an average estimate of -$0.05: beat by 374.6%
Revenue
$631m, up 2.8% on a year earlier
Share reaction
-29.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 3, 2026; average EPS estimate $0.18

Quidelortho's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.9%
  • 1 week+1.9%
  • 1 month+30.3%
  • This year-50.9%
  • 1 year-48.0%
  • 5 years-89.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.7B
Operating margin
-30.8%
Net margin
-39.2%
EPS (TTM, diluted)
$-15.39

Growth

Revenue growth
−2.5%
Change in growth rate
+1.4 pts
Share count change
+0.9%

Cash

Free cash flow (TTM)
-$211M
FCF margin
-7.9%
Stock pay % of revenue
1.7%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Announcement
  4. Leadership
  5. Announcement
  6. Agreement
  7. Announcement
  8. Results
  9. Results
  10. Announcement
  11. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Quidelortho Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Quidelortho Corp as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.18 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$39 ~$45–$190 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$39 ~$39–$190 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Quidelortho Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$179.65$134.99$85.67$73.70$44.25$29.30$14.03
Market value$7.8bn$5.8bn$4.9bn$4.9bn$3.0bn$2.0bn$956m
+ Net debt (− = net cash)−$490m−$802m$2.4bn$2.3bn$2.4bn$2.5bn$2.8bn
Enterprise value$7.3bn$5.0bn$7.3bn$7.2bn$5.4bn$4.5bn$3.7bn
Multiples
Price / sales 4.7x3.4x1.5x1.6x1.1x0.7x0.4x
Price / earnings 9.7x8.2x9.0x————
Price / free cash flow 13.9x11.3x6.6x69.4x———
EV / EBITDA 6.6x5.2x6.5x12.1x———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Quidelortho's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -7.3% of total assets over 5 years.

  • Durability 10 / 20

    Operating margin has been a median -8.5%; its worst year was -63.8%.

  • Cash conversion 6 / 20

    Free cash flow was positive in 3 of 5 years, at a median 0.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $628m and EPS of $0.18 (range $0.18 to $0.18) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.77 −64% $2.5bn −7%
Next $1.43 +85% $2.6bn +2%

Next year's EPS estimate has moved −41.9% in 90 days, across 2 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.05 $0.13 +374.6%
Mar 2026 $0.36 −$0.04 −111.2%
Dec 2025 $0.42 $0.46 +8.8%
Sept 2025 $0.47 $0.80 +71.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy133%
Hold133%
Sell133%

Monthly trend

  1. Oct 20261113
  2. Sep 20261113
  3. Aug 20261113
  4. Jul 20261113

Counts of recommendations published by analysts covering Quidelortho Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
29.7%
of tradable shares
Days to cover
11.1
at average volume
Short interest, 1 month
+6%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
0.9%
of shares
Employees
6,500
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −48.0%

$26.99 on October 31, 2025 to $14.03

ThenNowEffect
Revenue (last 12 months) $2.7bn $2.7bn −2.5%
P/S multiple 0.7x 0.4x −46.2%
Share count 68m 68m −0.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −78.2%

$64.27 on November 3, 2023 to $14.03

ThenNowEffect
Revenue (last 12 months) $3.2bn $2.7bn −15.4%
P/S multiple 1.4x 0.4x −73.8%
Share count 67m 68m −1.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
QDEL−25%−37%−14%−40%−36%−51%
Industry peers (median)−7%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
QDEL50%42%50%58%42%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
QDEL−59%−50%−38%−60%−59%−72%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 97% from August 5, 2020 to May 11, 2026. Getting back needed a 2932% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$9.96 – $35.38
From 52-week high
−60.3%
vs 50-day average
+10.1%
vs 200-day average
−13.1%
Volatility (1 year)
91%
Beta vs S&P 500
2.60

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±14.9%
After a week
3 up, 9 down
typical move ±11.4%
After a month
6 up, 6 down
typical move ±16.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −29.8% +0.5% −13.8% −20.2%
May 5, 2026 −11.8% +2.2% −10.5% +23.2%
April 15, 2026 −26.7% +1.0% −31.3% −34.2%
February 11, 2026 −18.7% −1.6% −19.2% −41.5%
November 5, 2025 −21.6% −0.7% −16.7% +2.3%
August 5, 2025 −2.8% +0.3% +4.5% +15.3%
May 7, 2025 +40.6% +1.1% +29.3% +13.8%
February 12, 2025 +0.4% +0.7% −1.1% −12.9%
January 13, 2025 −10.2% +0.3% −4.4% −12.7%
November 7, 2024 +9.5% +1.2% −2.5% +1.4%
July 31, 2024 +5.6% +0.2% −0.5% +9.6%
May 8, 2024 −0.6% +0.6% +2.5% −5.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Quidelortho Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Quidelortho Corp
$2.6B $2.8B $3B $3.2B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.1B Revenue (TTM), FY23 Q4: $3B Revenue (TTM), FY24 Q1: $2.9B Revenue (TTM), FY24 Q2: $2.8B Revenue (TTM), FY24 Q3: $2.8B Revenue (TTM), FY24 Q4: $2.8B Revenue (TTM), FY25 Q1: $2.8B Revenue (TTM), FY25 Q2: $2.7B Revenue (TTM), FY25 Q3: $2.7B Revenue (TTM), FY25 Q4: $2.7B Revenue (TTM), FY26 Q1: $2.7B Revenue (TTM), FY26 Q2: $2.7B $2.7B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.1B
FY23 Q4 $3B
FY24 Q1 $2.9B
FY24 Q2 $2.8B
FY24 Q3 $2.8B
FY24 Q4 $2.8B
FY25 Q1 $2.8B
FY25 Q2 $2.7B
FY25 Q3 $2.7B
FY25 Q4 $2.7B
FY26 Q1 $2.7B
FY26 Q2 $2.7B
Revenue growth, TTM YoY Quidelortho Corp
-15% -10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 2.8% Revenue growth, TTM YoY, FY23 Q4: -8.2% Revenue growth, TTM YoY, FY24 Q1: -7.9% Revenue growth, TTM YoY, FY24 Q2: -10.3% Revenue growth, TTM YoY, FY24 Q3: -9.7% Revenue growth, TTM YoY, FY24 Q4: -7.2% Revenue growth, TTM YoY, FY25 Q1: -3.4% Revenue growth, TTM YoY, FY25 Q2: -3.3% Revenue growth, TTM YoY, FY25 Q3: -3.7% Revenue growth, TTM YoY, FY25 Q4: -1.9% Revenue growth, TTM YoY, FY26 Q1: -3.9% Revenue growth, TTM YoY, FY26 Q2: -2.5% -2.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 2.8%
FY23 Q4 -8.2%
FY24 Q1 -7.9%
FY24 Q2 -10.3%
FY24 Q3 -9.7%
FY24 Q4 -7.2%
FY25 Q1 -3.4%
FY25 Q2 -3.3%
FY25 Q3 -3.7%
FY25 Q4 -1.9%
FY26 Q1 -3.9%
FY26 Q2 -2.5%
Operating margin (TTM) Quidelortho Corp
-80% -60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 5.9% Operating margin (TTM), FY23 Q4: 4.6% Operating margin (TTM), FY24 Q1: -60.0% Operating margin (TTM), FY24 Q2: -63.8% Operating margin (TTM), FY24 Q3: -64.6% Operating margin (TTM), FY24 Q4: -70.5% Operating margin (TTM), FY25 Q1: -6.2% Operating margin (TTM), FY25 Q2: -8.5% Operating margin (TTM), FY25 Q3: -35.1% Operating margin (TTM), FY25 Q4: -33.7% Operating margin (TTM), FY26 Q1: -37.0% Operating margin (TTM), FY26 Q2: -30.8% -30.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 5.9%
FY23 Q4 4.6%
FY24 Q1 -60.0%
FY24 Q2 -63.8%
FY24 Q3 -64.6%
FY24 Q4 -70.5%
FY25 Q1 -6.2%
FY25 Q2 -8.5%
FY25 Q3 -35.1%
FY25 Q4 -33.7%
FY26 Q1 -37.0%
FY26 Q2 -30.8%
FCF margin (TTM) Quidelortho Corp
-10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 4.7% FCF margin (TTM), FY23 Q4: 2.4% FCF margin (TTM), FY24 Q1: -4.1% FCF margin (TTM), FY24 Q2: -6.0% FCF margin (TTM), FY24 Q3: -3.4% FCF margin (TTM), FY24 Q4: -4.0% FCF margin (TTM), FY25 Q1: -1.3% FCF margin (TTM), FY25 Q2: 0.5% FCF margin (TTM), FY25 Q3: -5.6% FCF margin (TTM), FY25 Q4: -3.0% FCF margin (TTM), FY26 Q1: -6.0% FCF margin (TTM), FY26 Q2: -7.9% -7.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 4.7%
FY23 Q4 2.4%
FY24 Q1 -4.1%
FY24 Q2 -6.0%
FY24 Q3 -3.4%
FY24 Q4 -4.0%
FY25 Q1 -1.3%
FY25 Q2 0.5%
FY25 Q3 -5.6%
FY25 Q4 -3.0%
FY26 Q1 -6.0%
FY26 Q2 -7.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Jan 2021 2021 Jan 2022 2022 Jan 2023 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1,662 1,699 3,266 2,998 2,783 2,730 2,674
EBITDA 1,109 959 1,127 596 −1,508 −477 −371
Operating income 1,060 906 844 139 −1,961 −919 −825
Net income 810 704 549 −10 −2,052 −1,132 −1,048
Diluted EPS $18.60 $16.43 $9.56 −$0.15 −$30.54 −$16.69 −$15.39
Growth (year on year)
Revenue — +2.2% +92.3% −8.2% −7.2% −1.9% −2.5%
EBITDA — −13.6% +17.6% −47.1% −352.8% — −279.6%
Operating income — −14.6% −6.9% −83.5% <−999% — —
Net income — −13.1% −22.1% −101.8% — — —
Diluted EPS — −11.7% −41.8% −101.6% — — —
Margins
EBITDA margin 66.7% 56.4% 34.5% 19.9% −54.2% −17.5% −13.9%
Operating margin 63.8% 53.3% 25.8% 4.6% −70.5% −33.7% −30.8%
Net margin 48.8% 41.5% 16.8% −0.3% −73.7% −41.5% −39.2%
Free-cash-flow margin 34.0% 30.2% 22.8% 2.4% −4.0% −3.0% −7.9%
Cash flow
Cash from operations 630 806 885 280 83 105 −57
Capital spending 65 293 141 209 195 188 154
Free cash flow 565 513 744 71 −112 −83 −211
Stock-based pay 21 25 48 52 42 46 44
Free cash flow after stock pay 544 488 696 19 −154 −129 −256
Balance sheet
Cash 490 803 293 119 98 170 123
Total debt 0 1 2,649 2,424 2,489 2,701 2,893
Net debt (negative = net cash) −490 −802 2,356 2,305 2,390 2,531 2,770
Diluted shares 44m 43m 57m 67m 67m 68m 68m
Returned to shareholders
Buybacks 44 104 74 7 0 0 —
Total returned 44 104 74 7 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 28, 2026
What it owns · $5.7bn
Short-term assets $1.4bnLonger-term assets $4.3bn
What it owes, and who funded it · $5.7bn
Short-term liabilities $993mLonger-term liabilities $2.9bnShareholders' equity $1.8bn
  • Short-term assets cover short-term liabilities $1.4bn of assets due within a year against $993m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.4bn short-term assets against $2.9bn of longer-dated liabilities.
  • More cash than debt $123m of cash against $2.9bn of debt.
  • Debt below 40% of shareholders' equity Debt is 163% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 163% over five years.
  • A year's operating cash flow covers at least 20% of debt −$57m of operating cash flow against $2.9bn of debt.
  • Operating profit covers interest at least five times over Operating income of −$825m against $203m of interest.

From Quidelortho Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$7.2M
Diluted share count
+0.9%
year over year
R&D spending
6.8%
of revenue
Sales & admin spending
28.8%
of revenue
Days sales outstanding
48 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated QDEL RVTY PODD ENOV GMED TFX Median
Revenue, last 12 months $2.7bn $2.9bn $3.1bn $2.3bn $3.1bn $2.3bn $99m
Revenue growth, last 12 months −2.5% 4.1% 29.4% 4.9% 19.7% 30.7% 9.2%
Revenue growth, 3-year average −5.4% 0.9% 27.7% 12.2% 42.1% −8.0% 13.5%
Revenue growth, latest quarter 2.8% 1.3% 23.5% 3.2% 5.9% 28.9% 10.2%
Gross margin — 60.1% 71.1% 61.1% 68.5% 54.9% 61.2%
Operating margin −30.8% 12.3% 16.9% −45.1% 20.3% 2.0% −8.5%
Operating margin, 3-year average −34.4% 12.0% 16.2% −28.5% 11.4% 5.7% −17.9%
Net margin −39.2% 8.2% 12.3% −48.0% 17.0% −45.8% −12.0%
Cash from operations / revenue −2.1% 21.6% 16.7% 11.8% 28.9% 10.8% −1.9%
Free-cash-flow margin −7.9% 19.2% 9.0% 2.8% 24.0% 7.5% −3.9%
Free-cash-flow margin, 3-year average −4.5% 17.1% 11.6% −0.2% 17.1% 7.7% −7.0%
Stock pay / revenue 1.7% 0.3% 2.6% 1.5% 1.6% 1.1% 6.1%
Change in share count 0.9% −6.2% −3.6% 1.7% −1.4% −4.0% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -2.5% 9.1% 105 of 129
Change in growth rate Growth +1.4pp -0.6pp 39 of 129
Operating margin Profitability -30.8% -8.3% 80 of 132
Net margin Profitability -39.2% -12.0% 83 of 133
Free-cash-flow margin Cash generation -7.9% -3.4% 73 of 128
Stock pay as % of revenue Cash generation 1.7% 6.1% 27 of 123
Long-term debt as % of assets Balance sheet 44.4% 24.2% 71 of 87
Change in share count Balance sheet 0.9% 3.3% 41 of 115
Days sales outstanding Balance sheet 48 days 57 days 34 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 28, 2025
Geography
Region Revenue Share YoY
Domestic Country $1.4B 52.6% ▼ 8.4%
Foreign Country $1.3B 47.4% ▲ 6.5%

From Quidelortho Corp's 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.5B
Institutions reporting
240
Shares held vs prior quarter
▲ 1.0%
Positions opened / closed
53 / 47

Top buyers and sellers, Q2 2026: 138 institutions bought and 113 sold ; the biggest buyer was Newtyn Management, LLC (+2.1M shares) and the biggest seller T. Rowe Price Investment Management, Inc (−3.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $196M 11.2M 13.5% ▲ 7.2%
FMR LLC $129M 7.4M 8.9% ▲ 11.7%
Newtyn Management, LLC $116M 6.6M 8.0% ▲ 45.3%
Vanguard Portfolio Management LLC $72.4M 4.1M 5.0% ▲ 2.6%
Neuberger Berman Group LLC $62.1M 3.5M 4.3% ▲ 131.0%
Invesco Ltd. $60.8M 3.5M 4.2% ▲ 11.4%
American Century Companies Inc $57.9M 3.3M 4.0% ▲ 15.8%
Rubric Capital Management LP $57.9M 3.3M 4.0% 0.0%
Vanguard Capital Management LLC $53.8M 3.1M 3.7% ▲ 0.6%
State Street Corp $52.2M 3.0M 3.6% ▲ 6.9%
Paradigm Capital Management Inc $44.2M 2.5M 3.0% ▲ 65.3%
Private Management Group Inc $36.3M 2.1M 2.5% ▲ 49.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Quidelortho Corp's complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $1.3M 9 trades by 6 insiders, last 12 months Insider sales History → $111,963 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $1.2M net buying
Insider Date Trade Shares Price Value
Blaser Brian J. President and CEO February 13, 2026 Buy 10,540 $23.59 $248,639
Busky Joseph M. Chief Financial Officer February 13, 2026 Buy 3,370 $23.66 $79,734
Strobeck Matthew Director February 13, 2026 Buy 10,000 $23.96 $239,600
Busky Joseph M. Chief Financial Officer February 13, 2026 Buy 3,370 $23.66 $79,734
Rhoads Ann D Director December 10, 2025 Buy 750 $28.28 $21,210
Wilkins Joseph D Jr. Director November 26, 2025 Buy 370 $27.96 $10,345
Widder Kenneth J Director November 25, 2025 Sell 4,026 $27.81 $111,963
Busky Joseph M. Chief Financial Officer November 24, 2025 Buy 4,770 $26.06 $124,306
Polan Mary Lake Ph D Director November 21, 2025 Buy 1,000 $22.43 $22,430
Blaser Brian J. President and CEO November 19, 2025 Buy 23,500 $21.34 $501,490

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 14 trades and filings

No trades in Quidelortho Corp disclosed in the last 12 months; 14 earlier trades on record.

  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded July 12, 2023, filed August 13, 2023
  • Tom Malinowski(D-NJ 7):Purchase, $15,001 - $50,000, traded May 11, 2021, filed June 23, 2021
  • Tom Malinowski(D-NJ 7):Sale (full), $1,001 - $15,000, traded April 27, 2021, filed June 12, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 5, 2026
  • April 15, 2026
  • February 11, 2026
  • November 5, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Quidelortho Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Quidelortho Corp in brief

What does Quidelortho Corp do?
Quidelortho Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Quidelortho Corp's stock ticker?
Quidelortho Corp trades under the ticker QDEL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Quidelortho Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Quidelortho Corp reported revenue of $2.7B, 2.5% lower than a year earlier, according to its SEC filings.
What is Quidelortho Corp's free cash flow?
Quidelortho Corp's free-cash-flow margin is -7.9% of revenue over the trailing twelve months, ranking 73 of the 128 health care equipment companies we cover.
Who are Quidelortho Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., FMR LLC and Newtyn Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Quidelortho Corp's market cap?
On November 2, 2026, Quidelortho Corp's market capitalisation was about $956M and net debt of $2.8B. Market figures come from third-party market data and may be delayed.
How much debt does Quidelortho Corp have?
Quidelortho Corp's debt-to-equity ratio is 162.9%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Quidelortho Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Quidelortho Corp are Revvity, Insulet Corporation, Enovis Corp, Globus Medical Inc and Teleflex Inc. The side-by-side comparison below sets their revenue, margins and growth against Quidelortho Corp's.
Are insiders buying or selling Quidelortho Corp stock?
Over the last 12 months, Quidelortho Corp's directors and officers reported 9 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Quidelortho Corp's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Quidelortho Corp announces its own schedule.